Boston, MA 05/08/2014 (wallstreetpr) – AbbVie Inc (NYSE:ABBV) is a newly formed internationally recognized research based bio-pharmaceutical company. The company separated from Abbott Laboratories and set up its own identity with the dedicated personalities of the business. The company submitted its investigational report on the oral therapy on May 8, 2014.
AbbVie’s excellent contribution:
The latest news was indeed out of the box in the pharmaceutical industry. The bio-pharmaceutical company submitted its MAAs (marketing authorization applications) to EMA (European Medicines Agency). The application was issued for seeking approval for the ‘investigational, all oral, interferon free regimens for the treatment of the adult patients’ infected with chronic genotype-1 (GT1) hepatitis C virus (HCV).
Report analysis:
Marketing Authorization Applications has the data from the largest all oral, interferon free clinical program conducted on GT1 patients. The data consists of six Phase-III studies that were performed on 2,300 patients from more than 25 countries.
The VP’s quote:
The MD, Vice President of AbbVie Inc (NYSE:ABBV) said that the submission has the potential to prove its promising advancement for the GT1 Hepatitis C patients. He continued that this regulatory objective on the verge of the submission of a New Drug Application in America reflects a significant step for its portfolio.
European Medicines Agency has granted the company’s request for the new drugs on public health interest. The virus that has significant outburst in the whole world especially in European countries will get a positive solution very soon. The company that released its excellent financial report in April may satiate the investors as well as general people.
1Q2014 result better-than-expected:
AbbVie Inc (NYSE:ABBV), on the release of the financial report, stated that the revenue of AbbVie increased by 5.4% to $4.56 billion in the first quarter of the 2014. The estimated earnings per share also increased from $0.68 to $0.7. The overall estimation was completely left behind by the out-standing facts and figures of the business. The analyzers are quite sure that the latest news can affect on the upcoming second quarter!
